MoneyWorks4Me

USFDA concludes cGMP inspection at Cipla’s Bangalore facility

27 Jan 2020 Evaluate

United States Food and Drug Administration (USFDA) has concluded a cGMP inspection at Cipla’s API manufacturing facility in Bommasandra, Bangalore from January 20 - 24, 2020. The inspection ended with 4 observations which were procedural in nature and none of which were repeat or related to data integrity.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1416.00 -15.85 (-1.11%)
19-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1898.00
Dr. Reddys Labs. 1171.00
Cipla 1416.00
Lupin 2220.00
Zydus Lifesciences 1105.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: